Home Stock

Stock Research: Tvardi Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Tvardi Therapeutics

NAQ:TVRD US1407551092
28
  • Value
    38
  • Growth
    22
  • Safety
    Safety
    47
  • Combined
    23
  • Sentiment
    47
  • 360° View
    360° View
    28
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven and cancer cells. It operates in the biopharmaceutical industry with a focus on fibrosis-driven diseases (idiopathic pulmonary fibrosis, hepatocellular carcinoma) and cancer. The regions of operation are not specified in the description. In the last fiscal year, the company had a market cap of $234 million, profits of $7 million, revenue of $7 million, and 10 employees.

more

ANALYSIS: With an Obermatt 360° View of 28 (better than 28% compared with alternatives), overall professional sentiment and financial characteristics for the stock Tvardi Therapeutics are below the industry average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Tvardi Therapeutics. The consolidated Value Rank has a low rank of 38 which means that the share price of Tvardi Therapeutics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 62% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 22, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 22% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 47, which means that the company has a riskier financing structure than 53% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 47, which means that professional investors are more pessimistic about the stock than for 53% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Opinions Change
Country USA
Industry Pharmaceuticals
Size Small
Website tvarditherapeutics.com
Index
Tvardi Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
38 54 63 33
Growth
22 13 1 31
Safety
Safety
47 100 83 83
Sentiment
47 20 37 77
360° View
360° View
28 64 21 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
19 5 64 3
Opinions Change
90 50 50 72
Pro Holdings
n/a 12 12 99
Market Pulse
33 11 57 48
Sentiment
47 20 37 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
38 54 63 33
Growth
22 13 1 31
Safety Safety
47 100 83 83
Combined
23 85 18 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
5 20 34 33
Price vs. Earnings (P/E)
17 72 72 30
Price vs. Book (P/B)
83 95 89 50
Dividend Yield
1 1 1 1
Value
38 54 63 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
28 12 4 95
Profit Growth
75 76 23 1
Capital Growth
19 14 3 31
Stock Returns
1 23 3 37
Growth
22 13 1 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
64 100 100 100
Refinancing
3 96 99 47
Liquidity
81 1 29 29
Safety Safety
47 100 83 83

Similar Stocks

Discover high‑ranked alternatives to Tvardi Therapeutics and broaden your portfolio horizons.

Oracle

NYQ:ORCL
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews